Tristan Elliot Knight, MD, FRCPC

Tristan Elliot Knight, MD, FRCPC

Cancer and Blood Disorders Center, Inpatient Care – Acute care oncologists

On staff since October 2021

Children's Title: Attending Physician, Cancer and Blood Disorders Center

Academic Title: Clinical Assistant Professor, Pediatrics

"My goal is to help all parents, families, and children move from a place of confusion and fear to one of hope, optimism, acceptance, and confidence."

  • Dr. Tristan Knight is originally from Calgary, Canada, and completed his medical training at the Royal College of Surgeons in Ireland (RCSI) in Dublin, Ireland. He then moved to Honolulu, Hawaii, for his pediatric residency, followed by a hematology/oncology fellowship in Detroit, Michigan. This was followed by a bone marrow transplant/cellular therapy fellowship at SickKids, in Toronto, Canada. In his spare time, he is an avid runner and has completed multiple marathons. He also enjoys hiking, canoeing, skiing, and diving.

  • Award Name Award Description Awarded By Award Date
    Certificate of Appreciation 'In Recognition for Helping the BMT/CT Section Navigate COVID-19' Division of Pediatric Hematology and Oncology, The Hospital for Sick Children (SickKids) 2021
    Wolf W. Zuelzer Fellow Research Award 2018 ‘For outstanding research conducted during fellowship training' Children’s Hospital of Michigan 2018
    Chief’s Award 2016 ‘In Recognition of Volunteerism, Initiative, and Quest for Knowledge’ University of Hawaii Pediatric Residency Program. 2016
    Pediatric Infectious Diseases Excellence Award 2016 ‘In Recognition of Exceptional Dedication in Evaluating the Increasing Resistance Patterns of Infectious Agents in Pediatric Oncology Patients’ University of Hawaii Pediatric Residency Program 2016
  • Manuscripts in Refereed Journals

    • Oluwole OO, Dholaria B, Knight TE, Jain T, Locke FL, Ramsdell L, Nikiforow S, Hashmi H, Mooney K, Bhaskar ST, Morris K, Gatwood K, Baer B, Anderson LD Jr, Hamadani M.
      Chimeric Antigen Receptor T-Cell Therapy in the Outpatient Setting: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy
      Transplantation and Cellular Therapy, 2023 Nov 9
    • Knight TE, Ahn KW, Herbert KM, Atshan R, Wall DA, Chiengthong K, Lund TC, Prestidge T, Rangarajan HG, Dvorak CC, Auletta JJ, Kent M, Hashem H, Talano JA, Rotz SJ, Fraint E, Myers KC, Leung W, Sharma A, Bhatt NS, Driscoll TA, Yu LC, Schultz KR, Qayed M, Broglie L, Eapen M, Yanik GA
      No impact of CD34+ cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastoma
      Bone Marrow Transplantation, 2023
    • Knight TE, Ahn KW, Herbert KM, Atshan R, Wall DA, Chiengthong K, Rotz SJ, Fraint E, Rangarajan HG, Auletta JJ, Sharma A, Kitko CL, Hashem H, William KM, Wirk B, Dvorak CC, Myers KC, Pulsipher MA, Warwick AB, Lalefar NR, Schultz KR, Qayed M, Broglie L, Eapen M, Yanik GA.
      Effect of Autograft CD34+ Dose on Outcome in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System Tumors.
      Transplantation and Cellular Therapy, 2023
    • Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, Lin Y, Mahadeo KM, Maron GM, Marsh RA, Neelapu SS, Nikiforow S, Ombrello AK, Shah NN, Talleur AC, Turicek D, Vatsayan A, Wong SW, Maus MV, Komanduri KV, Berliner N, Henter JI, Perales MA, Frey NV, Teachey DT, Frank MJ, Shah NN.
      Immune Effector Cell associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
      Transplantation and Cellular Therapy, 2023
    • Knight TE, Edwards H, Meshinchi S, Taub JW, Ge Y
      "FLipping" the Story: FLT3-Mutated Acute Myeloid Leukemia and the Evolving Role of FLT3 Inhibitors.
      35884458 Cancers, 2022 Jul 13 : 14(14) PMCID:PMC9315611
    • Jain T, Knight T, Alencar MC, Davis L, Rao K, Im A, Malone AK, American Society for Transplantation and Cellular Therapy Committee on Education.
      American Society for Transplantation and Cellular Therapy Guidelines for Fellowship Training in Hematopoietic Cell Transplantation and Immune Effector Cell Therapy.
      34954294 Transplantation and cellular therapy, 2022 March : 28(3)125-133
    • Knight TE, Lowry J, Leppington S, Wall DA, Seelisch J
      Allogeneic hematopoietic stem cell transplantation in an adolescent with Prader-Willi syndrome - unique considerations.
      34128762 Pediatric hematology and oncology, 2022 Feb. : 39(1)89-95
    • Knight SWE, Knight TE, Santiago T, Murphy AJ, Abdelhafeez AH
      Malignant Peripheral Nerve Sheath Tumors-A Comprehensive Review of Pathophysiology, Diagnosis, and Multidisciplinary Management.
      35053663 Children (Basel, Switzerland), 2022 Jan 1 : 9(1) PMCID:PMC8774267
    • Knight TE, Ge Y, Taub JW, Hitzler J, Krueger J
      When it comes to drug access, should children be considered small adults? Countering coverage denials of FLT3 inhibitors in children with FLT3-ITD AML.
      34357678 Pediatric blood & cancer, 2021 Nov. : 68(11)e29278
    • Knight TE, Edwards H, Taub JW, Ge Y
      MAP4K1 expression is a novel resistance mechanism and independent prognostic marker in AML-but can be overcome via targeted inhibition.
      34280781 EBioMedicine, 2021 Aug. : 70103488 PMCID:PMC8318977
    • Qiao X, Ma J, Knight T, Su Y, Edwards H, Polin L, Li J, Kushner J, Dzinic SH, White K, Wang J, Lin H, Wang Y, Wang L, Wang G, Taub JW, Ge Y
      The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML.
      34099621 Blood cancer journal, 2021 Jun 7 : 11(6)111 PMCID:PMC8184771
    • Li X, Su Y, Hege K, Madlambayan G, Edwards H, Knight T, Polin L, Kushner J, Dzinic SH, White K, Yang J, Miller R, Wang G, Zhao L, Wang Y, Lin H, Taub JW, Ge Y
      The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia.
      32165486 Haematologica, 2021 May 1 : 106(5)1262-1277 PMCID:PMC8094102
    • Knight TE
      Severe Acute Respiratory Syndrome Coronavirus 2 and Coronavirus Disease 2019: A Clinical Overview and Primer.
      32726140 Biopreservation and biobanking, 2020 Dec. : 18(6)492-502
    • Knight T, Wait AB, Rajpurkar M
      Dyspnea in a Splenectomized 12-year-old Male with Hereditary Spherocytosis.
      33004574 Pediatrics in review, 2020 Oct. : 41(Suppl 1)S23-S26
    • Spruit JL, Knight T, Sweeney C, Salimnia H, Savaşan S
      Clostridium difficile infection in a children's hospital with specific patterns among pediatric oncology and hematopoietic stem cell transplantation populations.
      31994977 Pediatric hematology and oncology, 2020 April : 37(3)211-222
    • Knight T, Ravindranath Y, Callaghan MU
      Successful Treatment of an Adolescent Male With Severe Refractory Evans Syndrome Using Bortezomib-based Therapy.
      30299351 Journal of pediatric hematology/oncology, 2020 March : 42(2)e110-e113
    • Ma J, Zhao S, Qiao X, Knight T, Edwards H, Polin L, Kushner J, Dzinic SH, White K, Wang G, Zhao L, Lin H, Wang Y, Taub JW, Ge Y
      Inhibition of Bcl-2 Synergistically Enhances the Antileukemic Activity of Midostaurin and Gilteritinib in Preclinical Models of FLT3-Mutated Acute Myeloid Leukemia.
      31320594 Clinical cancer research : an official journal of the American Association for Cancer Research, 2019 Nov 15 : 25(22)6815-6826 PMCID:PMC6858954
    • Li X, Su Y, Madlambayan G, Edwards H, Polin L, Kushner J, Dzinic SH, White K, Ma J, Knight T, Wang G, Wang Y, Yang J, Taub JW, Lin H, Ge Y
      Antileukemic activity and mechanism of action of the novel PI3K and histone deacetylase dual inhibitor CUDC-907 in acute myeloid leukemia.
      30819918 Haematologica, 2019 Nov. : 104(11)2225-2240 PMCID:PMC6821619
    • Knight T, Zaidi AU, Wu S, Gadgeel M, Buck S, Ravindranath Y
      Mild erythrocytosis as a presenting manifestation of PIEZO1 associated erythrocyte volume disorders.
      31298594 Pediatric hematology and oncology, 2019 Aug. : 36(5)317-326
    • Knight S, Knight T, Khan A, Murphy AJ
      Current Management of Pleuropulmonary Blastoma: A Surgical Perspective.
      31349569 Children (Basel, Switzerland), 2019 Jul 25 : 6(8) PMCID:PMC6721434
    • Knight T, Glaser DW, Ching N, Melish M
      Antibiotic Susceptibility of Bloodstream Isolates in a Pediatric Oncology Population: The Case for Ongoing Unit-specific Surveillance.
      31033794 Journal of pediatric hematology/oncology, 2019 July : 41(5)e271-e276
    • Liu F, Knight T, Su Y, Edwards H, Wang G, Wang Y, Taub JW, Lin H, Sun L, Ge Y
      Venetoclax Synergistically Enhances the Anti-leukemic Activity of Vosaroxin Against Acute Myeloid Leukemia Cells Ex Vivo.
      31115744 Targeted oncology, 2019 June : 14(3)351-364
    • Savaşan S, Wakeling E, Knight T, Buck S, Gadgeel M
      Different Clonal T-Large Granular Lymphocyte Proliferations in SCID.
      30919140 Journal of clinical immunology, 2019 April : 39(3)245-248
    • Knight T, Luedtke D, Edwards H, Taub JW, Ge Y
      A delicate balance - The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics.
      30668936 Biochemical pharmacology, 2019 April : 162250-261
    • Knight T, Shatara M, Carvalho L, Altinok D, Poulik J, Wang ZJ
      Dramatic response to trametinib in a male child with neurofibromatosis type 1 and refractory astrocytoma.
      30251337 Pediatric blood & cancer, 2019 Jan. : 66(1)e27474
    • Wang T, Shatara M, Liu F, Knight T, Edwards H, Wang G, Lin H, Wang Y, Taub JW, Ge Y
      Simultaneous cotargeting of ATR and RNA Polymerase I transcription demonstrates synergistic antileukemic effects on acute myeloid leukemia.
      31700693 Signal transduction and targeted therapy, 2019 : 444 PMCID:PMC6823485
    • Knight T, Edwards H, Taub JW, Ge Y
      Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia.
      31118772 Cancer management and research, 2019 : 113197-3213 PMCID:PMC6499443
    • Knight T, Callaghan MU
      The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A.
      30344994 Therapeutic advances in hematology, 2018 Oct. : 9(10)319-334 PMCID:PMC6187429
    • Knight T, Kotz K, Savaşan S
      Autoimmune thyroiditis following HLA-matched sibling hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome.
      29761856 Pediatric transplantation, 2018 Aug. : 22(5)e13222
    • Knight T, Savaşan S
      Megakaryocytic Emperipolesis in an Adolescent With Hodgkin Lymphoma.
      29401103 Journal of pediatric hematology/oncology, 2018 May : 40(4)306
    • Knight TE, Shiramizu B, Ly P, Thompson KS, Reddy V
      Paroxysmal Nocturnal Dyspnea Secondary to Right Ventricular Myxoma: A Novel Presentation of an Unusual Tumor.
      29682382 Case reports in pediatrics, 2018 : 20184791379 PMCID:PMC5851333
    • Knight TE, Knight SW, Kyono W, Thompson K, Hicks J, Shiramizu B
      Peripheral Primitive Neuroectodermal Tumor and Neurofibromatosis Type 1 in an Adolescent Male.
      26828586 Pediatric blood & cancer, 2016 July : 63(7)1310-1 PMCID:PMC4877260
    • Takiguchi M, Knight T, Nguyen TT, Limm B, Hayes D, Reddy V, Bratincsak A
      Underdiagnosis of Conditions Associated with Sudden Cardiac Death in Children--Is it the Absence of a Comprehensive Screening Program or a True Low Prevalence?
      26918207 Hawai'i journal of medicine & public health : a journal of Asia Pacific Medicine & Public Health, 2016 Feb. : 75(2)42-5 PMCID:PMC4755066
    • Knight T, Steeves T, Day L, Lowerison M, Jette N, Pringsheim T
      Prevalence of tic disorders: a systematic review and meta-analysis.
      22759682 Pediatric neurology, 2012 Aug. : 47(2)77-90
  • Presentations Title Event Location Date
    Impact of CD34+ Cell Dose on Outcome Among Children Undergoing Autologous Hematopoietic Stem Cell Transplant for High-Risk Neuroblastomas. Center for International Blood and Marrow Transplant Research (CIBMTR) Pediatric Cancer Working Committee - Transplant and Cellular Therapy (TCT) Meetings Salt Lake City, Utah 2022
    Effect of Autograft CD34 + Dose on Outcome in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplant for Central Nervous System Tumors Center for International Blood and Marrow Transplant Research (CIBMTR) Pediatric Cancer Working Committee - Transplant and Cellular Therapy (TCT) Meetings Salt Lake City, Utah 2022
    There and Back Again - Strategies for Successful US Fellowship Matches and Job Searches. University of Toronto School of Medicine - Clinician Investigator Program (CIP). Virtual 2022
    Understanding COVID-19 International Society for Biological and Environmental Repositories (ISBER). Virtual 2020
    COVID-19 for Bone Marrow Transplant/Cellular Therapy (BMT/CT) Programs Cell Therapy Transplant Canada (CTTC). Virtual 2020
    Autologous graft cell dose and post-transplant granulocyte colony stimulating factor in posttransplant outcomes among pediatric patients undergoing autologous hematopoietic stem cell transplantation. CIBMTR Proposal 1911-14 Center for International Blood and Marrow Transplant Research (CIBMTR) Pediatric Cancer Working Committee - Transplant and Cellular Therapy (TCT) Meetings Orlando, Florida 2020
    Clawtooth Mountain: The “Good Journey” of a Baby with Severe Combined Immunodeficiency American Society of Pediatric Hematology/Oncology (ASPHO) Clinical Immunology Special Interest Group. Virtual 2019
  • Grant Title Grantor Amount Award Date
    Garron Family Cancer Center Research Fellowship / BMO Financial Group Oncology Fellowship 2020
    Hold’em for Life Oncology Fellowship 2020
    The Ashok & Ingrid Sarnaik Endowment for Resident and Fellow Research 2018
    The Children’s Hospital of Michigan Foundation 2018


Board Certification(s)

Pediatric Hematology-Oncology

Medical/Professional School

Royal College of Physicians & Surgeons-Ireland, Dublin


Kapiolani Medical Center for Women, Honolulu, HI


Children's Hospital of Michigan GME, Detroit, MI
Hospital for Sick Children, University of Toronto, Toronto, ON

Clinical Interests

Allogeneic hematopoietic stem cell transplantation, Autologous hematopoietic stem cell transplantation, Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Cellular/Immune Effector Cell Therapy, Chimeric Antigen Receptor T-cell (CAR-T) Therapy, Neuroblastoma.